Beyond Meat (BYND) vs Clene (CLNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Clene (CLNN) has outperformed Beyond Meat (BYND) over the past year, losing 58.8% versus a loss of 87.6%. Over five years, CLNN leads with a -96.9% price change compared with -99.8% for BYND. Beyond Meat is the larger company by market cap ($132.9 million vs $55.2 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BYND | CLNN |
|---|---|---|
| Share price | $7.73 | $3.88 |
| Market cap | $132.91M | $55.15M |
| 1-day change | +0.91% | -1.02% |
| YTD return | -68.58% | -33.90% |
| 1-year return | -87.61% | -58.81% |
| 5-year return | -99.76% | -96.86% |
| EPS (TTM) | $-23.40 | $-3.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $230.70 | $13.50 |
| 52-week low | $7.50 | $3.25 |
| Distance from 52-week high | -96.65% | -71.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +61.71% | +729.90% |
| Average volume | 1.38M | 100.21K |
| Shares outstanding | 17.19M | 14.21M |
| Employees | 589 | 76 |
| Sector | Consumer Staples | Consumer Defensive |
| Industry | Packaged Foods | Packaged Foods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Beyond Meat is about 2.4 times larger than Clene by market value ($132.91M vs $55.15M).
- CLNN has outperformed BYND by 28.8 percentage points over the past year.
- The two companies sit in different sectors: Beyond Meat in Consumer Staples and Clene in Consumer Defensive.
About Beyond Meat
BYND stock →Beyond Meat, Inc., a plant-based meat company, engages in the development, manufacture, marketing, and sale of plant-based meat products under the Beyond brand name in the United States and internationally. The company sells a range of plant-based meat products that replicates beef, pork, and poultry meats.
Consumer Staples · Packaged Foods · 589 employees
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Consumer Defensive · Packaged Foods · 76 employees
BYND vs CLNN FAQ
Which is bigger, Beyond Meat or Clene?
Beyond Meat (BYND) is larger, with a market capitalization of $132.91M compared with $55.15M for Clene (CLNN).
Which stock has performed better over the past year, BYND or CLNN?
CLNN returned -58.81% over the past 12 months, compared with -87.61% for BYND (price return, excluding dividends). Past performance does not predict future results.
Are Beyond Meat and Clene in the same industry?
Yes. Both are classified in the Packaged Foods industry within the Consumer Staples sector.